Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed solid tumors that have been shown to
overexpress clusterin, including but not limited to, any of the following:

- Prostate cancer

- Renal cell carcinoma

- Non-small cell lung cancer

- Bladder cancer

- Breast cancer

- Ovarian cancer

- Metastatic or locally recurrent disease

- Refractory to standard curative therapy or no standard curative therapy exists

- Patients with prostate cancer must be hormone refractory (i.e., have documented
evidence of progression while receiving androgen ablative therapy)

- Measurable or nonmeasurable disease

- Measurable disease defined as measurable lesion ≥ 20 mm by x-ray, physical exam,
or nonspiral CT scan or ≥ 10 mm by spiral CT scan

- No documented CNS metastases

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Menopausal status not specified

- ECOG performance status 0-2

- Life expectancy ≥ 12 weeks

- Absolute granulocyte count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Bilirubin normal

- Creatinine ≤ 2 times upper limit of normal (ULN)

- AST and ALT ≤ 1.5 times ULN

- PT/INR and PTT normal

- No uncontrolled pain

- No known bleeding disorder

- No history of serious allergic reaction to taxane (paclitaxel or docetaxel)

- No preexisting peripheral neuropathy ≥ grade 2

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other serious illness or medical conditions that would preclude study compliance,
including any of the following:

- Active uncontrolled infection

- Significant cardiac dysfunction

- No significant neurological disorder that would preclude giving informed consent

PRIOR CONCURRENT THERAPY:

- No prior strontium chloride Sr 89

- No more than 2 prior chemotherapy regimens, including adjuvant or neoadjuvant
chemotherapy (for patients assigned to schedule B [docetaxel once every 3 weeks])

- More than 4 weeks since prior chemotherapy and recovered

- At least 4 weeks since prior antiandrogens

- More than 4 weeks since prior external-beam radiotherapy, except low-dose
nonmyelosuppressive radiotherapy

- No prior radiotherapy to ≥ 30% of marrow-bearing areas (for patients assigned to
schedule B [docetaxel once every 3 weeks])

- At least 28 days since prior new anticancer therapy

- At least 28 days since prior and no other concurrent investigational agents

- No concurrent radiotherapy, except low-dose nonmyelosuppressive radiotherapy

- No other concurrent cytotoxic therapy

- Concurrent luteinizing hormone-releasing hormone agonist allowed (if already
initiated in patients with prostate cancer)

- No concurrent anticoagulant therapy (i.e., heparin, warfarin)